4.6 Article

Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology

Journal

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 14, Issue 4, Pages 1279-1287

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2018.03.001

Keywords

Surface enhanced Raman spectroscopy (SERS); Cancer detection; Urine; Transitional cell carcinoma (TCC); Liquid biopsy

Funding

  1. Institute for Collaborative Biotechnologies from the U.S. Army Research Office [W911NF-09-0001]
  2. University of California Cancer Research Coordinating Committee

Ask authors/readers for more resources

Canine lower urinary tract neoplasia is a clinically important disease process that has high mortality due to late stage diagnosis and poorly durable response to treatment. Non-invasive diagnostic techniques (e.g. dipstick test, urine cytology) currently have poor diagnostic value, while more invasive tests (e.g. cystoscopy and biopsy) are costly and often require general anesthesia. We have developed and herein describe a quantitative cytological analysis method based on the use of surface-enhanced Raman spectroscopy (SERS), for identifying cancerous transitional cells in urine using SERS biotags (SBTs) carrying the peptide PLZ4 (amino acid sequence cQDGRMGFc) that targets malignant transitional cells. By analyzing the ratio of the PLZ4-SBTs to an on board control we were able to show that transitional cells had significantly higher ratios (P < 0.05) in patients diagnosed with transitional cell carcinoma (TCC) than in healthy samples. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available